The effects of chronic kidney disease in ischemic cardiomyopathy

The effect of chronic kidney disease in ischemic cardiomyopathy: Long-term follow-up - REVISION-DM2 Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN17786790

Enrollment

918

Registered

2018-08-22

Start date

2011-05-25

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease in ischemic cardiomyopathy Urological and Genital Diseases Chronic kidney disease in ischemic cardiomyopathy

Interventions

This study will include 2160 patients with coronary artery disease (CAD) previously treated by surgery, percutaneous revascularization, or medical treatment in an outpatient follow-up for 5 years. The

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Stable angina 2. Multi-vessel coronary artery disease 3. Had an evaluation of left ventricular function 4. Aged 18 years or older

Exclusion criteria

Exclusion criteria: 1. In dialysis programs 2. Pacemaker 3. Defibrillators 4. Reduced life expectancy 5. Degenerative diseases

Design outcomes

Primary

Measure	Time frame
The following are assessed throughout the study, from the date of inclusion to the end of the study: 1. Mortality from any cause 2. Non-fatal myocardial infarction, defined as the following: 2.1. Elevation of specific cardiac enzymes within 14 days of a revascularization procedure 2.2. Presence of new Q waves in at least 2 or more contiguous leads 2.3. CK-MB (creatine kinase-muscle/brain)( or troponin US elevation, 10 times above normal level 3. Unplanned cardiac surgery - the need for unplanned revascularization, after symptoms of angina after coronary surgery with or without cardiopulmonary bypass 4. Stroke, defined as one of the following: 4.1. Patients with a focal neurological deficit of central origin, lasting more than 72 hours 4.2. Focal neurological deficit of central origin, lasting more than 24 hours, with imaging evidence of cerebral infarction or intracerebral haemorrhage 4.3. Non-focal encephalopathy, with imaging evidence of cerebral infarction 4.4. Haemorrhage adequate to account for the clinical state 5. Hospital admissions for cardiac causes, including the following: 5.1. Anginal symptoms 5.2. Heart failure 5.3. Generalized edema 5.4. Cardiac arrhythmia 6. Hospital admissions for renal causes, including the following: 6.1. Loss of urinary volume 6.2. Increase of plasmatic potassium without specific cause 6.3. Generalised edema	—

Measure

Time frame

The following are assessed throughout the study, from the date of inclusion to the end of the study: 1. Mortality from any cause 2. Non-fatal myocardial infarction, defined as the following: 2.1. Elevation of specific cardiac enzymes within 14 days of a revascularization procedure 2.2. Presence of new Q waves in at least 2 or more contiguous leads 2.3. CK-MB (creatine kinase-muscle/brain)( or troponin US elevation, 10 times above normal level 3. Unplanned cardiac surgery - the need for unplanned revascularization, after symptoms of angina after coronary surgery with or without cardiopulmonary bypass 4. Stroke, defined as one of the following: 4.1. Patients with a focal neurological deficit of central origin, lasting more than 72 hours 4.2. Focal neurological deficit of central origin, lasting more than 24 hours, with imaging evidence of cerebral infarction or intracerebral haemorrhage 4.3. Non-focal encephalopathy, with imaging evidence of cerebral infarction 4.4. Haemorrhage adequate to account for the clinical state 5. Hospital admissions for cardiac causes, including the following: 5.1. Anginal symptoms 5.2. Heart failure 5.3. Generalized edema 5.4. Cardiac arrhythmia 6. Hospital admissions for renal causes, including the following: 6.1. Loss of urinary volume 6.2. Increase of plasmatic potassium without specific cause 6.3. Generalised edema

—

Secondary

Measure	Time frame
Quality of life, assessed every 6 months for 5 years using a questionnaire evaluating topics including the following: 1. Pain 2. Vitality 3. Emotional aspects 4. Physical aspects	—

Countries

Brazil

Contacts

Public ContactThiago Hueb

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 21, 2026